Hot Blue Chip Stocks To Own Right Now

p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; text-align: justify; font: 13.0px Verdana; -webkit-text-stroke: #000000} span.s1 {font-kerning: none}

Dow 19,000 has a nice ring to it. And the iconic blue chip stock gauge is edging ever closer to that milestone.

After Mondays record-breaking day, when the Dow Jones industrial average, large-company Standard & Poors 500 stock index, tech-dominated Nasdaq composite and the small-cap Russell 2000 all closed at record levels at the same time for the first time since Dec. 31, 1999, the Dow is on the verge of making more headlines and getting a big shout outon the evening news.

.oembed-asset-link { border-bottom: 1px solid #e1e1e1; } .oembed-link-anchor { display: block; clear: both; } .oembed-link-thumbnail{ float: left; padding: 14px; } .oembed-link-thumbnail img { max-width: 78px; max-height: 60px; display: block; } p.oembed-link-title { font-size: 75%; color: #009BFF; margin: 0 14px; padding-top: 12px; font-weight:normal; text-align: left; line-height: 120%; } p.oembed-link-desc { font-size: 100%; color: #666; font-weight: normal; margin: 0 14px 14px 14px; font-family: ‘Futura Today Light’; text-align: left; line-height: 120%; }

USA TODAY

Hot Blue Chip Stocks To Own Right Now: Ultragenyx Pharmaceutical Inc.(RARE)

Advisors’ Opinion:

  • [By Shane Hupp]

    These are some of the media headlines that may have effected Accern’s scoring:

    Get Ultragenyx Pharmaceutical alerts:

    Burosumab Improves Outcomes in Children with XLH in Phase 2 Trial (raredr.com) RARE Stock Is on the Verge of Breaking Out Toward Higher Prices (profitconfidential.com) Burosumab may benefit children with X-linked hypophosphatemia (medicalxpress.com) A Look Inside the Quant Data For Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE) (parkcitycaller.com) Ultragenyx Pharmaceutical Inc. (RARE)- Stock in the Trader’s Radar (nasdaqfortune.com)

    A number of research firms have recently weighed in on RARE. ValuEngine raised Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday. BidaskClub raised Ultragenyx Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 19th. Barclays raised Ultragenyx Pharmaceutical from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $62.00 to $74.00 in a report on Friday, May 11th. Goldman Sachs Group began coverage on Ultragenyx Pharmaceutical in a report on Thursday, May 10th. They set a “neutral” rating and a $63.00 target price for the company. Finally, Zacks Investment Research downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $70.06.

  • [By Joseph Griffin]

    BidaskClub upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a hold rating to a buy rating in a report released on Monday.

    A number of other brokerages have also recently weighed in on RARE. JPMorgan Chase restated an overweight rating and issued a $66.00 price objective (down from $68.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. Evercore ISI upgraded shares of Ultragenyx Pharmaceutical from an in-line rating to an outperform rating in a research note on Monday, January 22nd. Stifel Nicolaus restated a buy rating and issued a $74.00 price objective (down from $85.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. ValuEngine upgraded shares of Ultragenyx Pharmaceutical from a sell rating to a hold rating in a research note on Wednesday, April 4th. Finally, Wedbush reiterated a positive rating and set a $71.00 target price (up from $64.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, April 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have issued a buy rating to the company. Ultragenyx Pharmaceutical presently has a consensus rating of Buy and an average price target of $69.76.

  • [By Shane Hupp]

    Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Director Matthew K. Fust sold 6,319 shares of the business’s stock in a transaction that occurred on Wednesday, May 30th. The shares were sold at an average price of $72.00, for a total value of $454,968.00. Following the transaction, the director now owns 8,750 shares of the company’s stock, valued at $630,000. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Todd Campbell]

    A Genentech alumnus, Conner was previously vice president of clinical science at Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biotech that has successfully developed therapies for rare and ultrarare diseases. Prior to that, he was senior medical director at BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), another biotech company that’s successfully developed drugs for rare diseases.

Hot Blue Chip Stocks To Own Right Now: GlobalSCAPE, Inc.(GSB)

Advisors’ Opinion:

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Akorn, Inc. (NASDAQ: AKRX) fell 32.7 percent to $13.25 in pre-market trading after Fresenius terminated its merger deal with Akorn.
    Chicago Bridge & Iron Company N.V. (NYSE: CBI) fell 15.7 percent to $12.30 in pre-market trading. Subsea 7 confirmed a $7.00 per share proposal to acquire Mcdermott, pending termination of merger agreement with CB&I.
    Myomo, Inc. (NYSE: MYO) fell 9 percent to $3.65 in pre-market trading after rising 11.39 percent on Friday.
    Hasbro, Inc. (NASDAQ: HAS) fell 8 percent to $88.36 in pre-market trading after the company reported weaker-than-expected results for its first quarter on Monday.
    SunPower Corporation (NASDAQ: SPWR) fell 7.1 percent to $9.00 in pre-market trading.
    Endeavour Silver Corp. (NYSE: EXK) shares fell 5.9 percent to $2.88 in pre-market trading after declining 3.16 percent on Friday.
    Mattel, Inc. (NASDAQ: MAT) shares fell 5.5 percent to $12.25 in pre-market trading.
    Valeritas Holdings, Inc. (NASDAQ: VLRX) shares fell 5.1 percent to $2.96 in pre-market trading after rising 76.27 percent on Friday.
    GlobalSCAPE, Inc. (NYSE: GSB) fell 5.1 percent to $3.57 in pre-market trading.
    Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) shares fell 4.1 percent to $49.93 in pre-market trading.
    Oasis Petroleum Inc. (NYSE: OAS) fell 4.1 percent to $9.75 in pre-market trading. SunTrust Robinson Humphrey downgraded Oasis Petroleum from Hold to Sell

Hot Blue Chip Stocks To Own Right Now: (LVMUY)

Advisors’ Opinion:

  • [By Shane Hupp]

    LVMH Moet Hennessy Louis Vuitton (OTCMKTS:LVMUY) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Saturday.

  • [By ]

    French luxury house LVMH SE (LVMUY) stock surged 3.55% in Paris, changing hands at 278.8 after it reported better-than-expected first quarter sales. Organic revenues rose by 13% in the first three months of the year, driven by its fashion and leather goods division.

  • [By Leo Sun]

    At $126, Tiffany trades at about 27 times this year’s earnings estimate — which is a premium valuation relative to the midpoint of its forecast for 12% growth. LVMH (NASDAQOTH:LVMUY), which owns Tiffany’s rival(and Bogliolo’s former employer) Bulgari, trades at just 25 times this year’s earnings — and analysts expect its EPS to jump 16%. Bulgari, like Tiffany, is pivoting away fromits “old world” charms toward edgier marketing campaigns that target younger shoppers.

  • [By ]

    Two years ago, I discussed LVMH (OTCPK:LVMUY) (OTCPK:LVMHF) in another article here on Seeking Alpha. Although I wasnt too impressed with the companys free cash flow yield, I did agree this company deserved a premium valuation. And on top of that, I was expecting its strong growth results to continue in the years ahead. Were now two years later, and LVMH has delivered on every front. Unfortunately the market caught up on that as well, and LVMHs share price has doubled in just two years. And although the LVMH results justify a good performance of the share price, I do think LVMH is getting a little pricey.

Hot Blue Chip Stocks To Own Right Now: Aerojet Rocketdyne Holdings, Inc. (AJRD)

Advisors’ Opinion:

  • [By Rich Smith]

    Aerojet Rocketdyne (NYSE:AJRD) stock lost 12% of its value in the two days after the company reported earnings for the first quarter of 2018 — a miss, and its third such miss in a row, according to data from Yahoo! Finance. Since that report and subsequent drop, however, Aerojet Rocketdyne has come roaring back, recovering all of its losses, and even adding a bit more.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Aerojet Rocketdyne (AJRD)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Rich Smith]

    In fact, Boeing and Lockheed Martin look to be two-time winners, as the second largest bump in funding is going to help pay for deep space missions, and to NASA’s Orion crew vehicle and Space Launch System (SLS), which are designed to carry them. Orbital ATK (soon to be absorbed into Northrop Grumman) and Aerojet Rocketdyne (NYSE:AJRD) are other key players on the SLS project. Congress wants to pour an additional $294 million into this program, funding it with $5.1 billion next year.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Aerojet Rocketdyne (AJRD)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Leave a Reply

Your email address will not be published. Required fields are marked *